Abstract
Background: Clozapine (CLZ) is an atypical antipsychotic mainly prescribed for treatment-resistant schizophrenia. Beyond psychotic symptoms, patients often exhibit persistent cognitive impairments across domains such as attention, learning, and memory. The mechanisms by which CLZ may influence cognition and provide neuroprotection are not fully elucidated. Accordingly, this study examined how CLZ modulates lipopolysaccharide (LPS)-induced neurotoxicity in rats. Method: Rats were administered LPS to induce cognitive impairment and subsequently treated with CLZ. Behavioral assessments were performed using maze tests (elevated plus-maze (EPM), novel object recognition (NOR), and Y-maze). Biochemical analyses included cholinergic function (acetylcholine (ACh)), neurodegeneration-associated enzymes (glycogen synthase kinase-3 beta (GSK-3β), β-site amyloid precursor protein cleaving enzyme-1 (BACE-1), and dipeptidyl peptidase-4 (DPP-4)), oxidative stress markers (lipid Peroxidation (LPO), catalase, and reduced glutathione (GSH)), and apoptotic proteins (B-cell lymphoma-2 (Bcl-2), Bcl-2-associated X protein (Bax), and cleaved Caspase-3 (c-Caspase-3)). Results: CLZ treatment markedly improved performance in EPM, NOR, and Y-maze tasks, indicating recovery of cognitive function in LPS-exposed rats. At the molecular level, CLZ enhanced ACh levels, upregulated the anti-apoptotic protein Bcl-2, and restored antioxidant defenses (catalase and GSH). Conversely, CLZ reduced LPS-induced neurotoxicity by lowering GSK-3β activity, LPO, and pro-apoptotic markers (Bax and c-Caspase-3). Conclusion: The findings demonstrate that CLZ exerts neuroprotective effects in an LPS-induced rat model, improving cognition through modulation of cholinergic transmission, oxidative stress, and apoptosis pathways. These results clarify key mechanistic pathways through which CLZ may exert cognitive benefits and highlight its potential relevance for improving schizophrenia-related cognitive dysfunction. Further molecular studies are warranted to confirm and extend these observations toward clinical translation.
1. Introduction
Psychiatric disorders are increasingly recognized not only as conditions that impair mental health, but also as contributors to long-term cognitive decline and dementia [1]. Psychosis, for example, is marked by a loss of contact with reality and is expressed through a cluster of symptoms that distort thought, perception, and behavior. Schizophrenia is a long-term psychiatric illness that affects roughly one percent of people worldwide and is regarded as one of the principal manifestations of psychosis. The disorder typically presents with a combination of symptom domains, including positive symptoms (e.g., delusions and hallucinations), negative symptoms such as reduced motivation and social withdrawal, and enduring cognitive impairments that impact processes like attention, learning, and memory [2]. Recent systematic reviews and meta-analyses have highlighted that non-affective psychiatric disorders significantly increase vulnerability to dementia and cognitive decline [3]. Individuals with these disorders often show accelerated brain aging, structural alterations in cortical and hippocampal regions, and reduced neuroplasticity. Together, these changes may predispose patients to cognitive impairment later in life, underscoring the need for close monitoring and timely interventions aimed at preserving cognitive acuity [4].
Importantly, cognitive decline is also the hallmark of dementia, where the majority of patients progressively lose memory and executive abilities. Beyond cognitive deficits, up to 80–90% of individuals with dementia exhibit a spectrum of behavioral and psychological symptoms of dementia (BPSD), including psychosis, anxiety, depression, agitation, and sleep disturbances [5,6]. Such non-cognitive disturbances substantially increase overall disease burden, hasten functional deterioration, and impose considerable emotional and practical strain on caregivers [7]. Emerging evidence suggests that psychiatric disorders may heighten susceptibility to dementia-related neurodegeneration rather than directly initiating it. Epidemiological data indicate substantial variability in the prevalence of psychosis across dementia subtypes. Among neurodegenerative disorders, the highest rates are observed in dementia with Lewy bodies (DLB), where up to three-quarters of patients are affected, followed by Alzheimer’s disease (AD; around half of cases) and frontotemporal degeneration (FTD; roughly 40%). In particular, visual hallucinations are especially characteristic of DLB, while delusions are more frequently observed in AD [8,9]. In routine practice, clinicians often prescribe typical or atypical antipsychotics off-label to manage psychosis in dementia, irrespective of the underlying subtype [10].
Neuropathological studies suggest that neurodegeneration forms an important bridge between schizophrenia and dementia, two conditions commonly linked with psychosis and progressive cognitive decline. Disturbances in cholinergic and dopaminergic signaling are particularly critical, as they underlie impairments in learning, memory, and behavioral control [11]. Cholinergic pathways arising from the basal forebrain and projecting to cortical and hippocampal circuits are fundamental for attentional processing and memory formation. Degeneration within this system leads to a reduction in acetylcholine (ACh) availability, a change that has been consistently linked to impairments in learning and cognitive performance [12]. Within the striatum, cholinergic interneurons shape dopamine release through their regulation of GABAergic and glutamatergic terminals [13]. In return, dopamine influences cholinergic activity via D2 and D5 receptors, forming a feedback loop. Disturbance of this balance results in abnormal cholinergic signaling, a mechanism thought to drive both cognitive decline and psychotic symptoms in neurodegenerative and psychiatric disorders [14].
Neuronal damage sets off a series of enzymatic changes that accelerate neurodegeneration. Glycogen synthase kinase-3β (GSK-3β) is one of the key regulators in this process; its overactivity promotes tau phosphorylation, synaptic disruption, and neuronal loss, changes commonly linked with both AD and schizophrenia [15]. Another enzyme, β-site amyloid precursor protein cleaving enzyme-1 (BACE-1), drives the production of amyloid-β, whose accumulation leads to plaque formation and contributes to memory decline and psychotic features in dementia [16]. Dipeptidyl peptidase-4 (DPP-4), traditionally associated with glucose metabolism, is increasingly recognized for its role in the brain, where it enhances oxidative stress, neuroinflammation, and apoptosis, thereby worsening neuronal vulnerability [17]. In addition to enzyme-related disturbances, oxidative stress is widely recognized as a critical factor in neurodegeneration. When reactive oxygen species (ROS) accumulate beyond physiological limits, they damage vital cellular structures such as lipids, proteins, and DNA. A decline in antioxidant defenses, particularly enzymes like catalase and molecules such as glutathione, further increases neuronal susceptibility to injury [18,19]. This redox imbalance activates apoptotic signaling, marked by a reduction in the protective protein B-cell lymphoma-2 (Bcl-2) and upregulation of pro-apoptotic factors including Bcl-2-associated X protein (Bax) and cleaved Caspase-3 (c-Caspase-3), which together promote neuronal death [20]. The combined influence of oxidative stress, apoptosis, and enzyme dysregulation provides a mechanistic basis for the overlapping patterns of cognitive impairment and psychotic symptoms observed in dementia and schizophrenia.
Clozapine (CLZ) was the first atypical antipsychotic introduced for patients with schizophrenia and schizoaffective disorder who did not respond adequately to conventional agents. Its therapeutic effect arises largely from combined dopamine and serotonin antagonism, with notable activity at D4 and 5-HT2A receptors. However, the clinical use of CLZ is constrained by serious side effects, most prominently agranulocytosis and, less frequently, toxic hepatitis [21]. Beyond its established antipsychotic action, evidence suggests that second-generation (atypical) antipsychotics, including CLZ, may also exert neuroprotective effects, ranging from preventive to restorative, potentially offsetting neurodegenerative processes associated with psychosis [22].
Experimental studies demonstrate that CLZ reduces microglial over-activation, limiting pro-inflammatory cytokine release and preserving dopaminergic neurons by inhibiting PHOX-driven reactive oxygen species production [23]. Recent reviews emphasize that these anti-inflammatory actions likely contribute significantly to therapeutic outcomes, alongside receptor-based mechanisms [24]. CLZ has additionally been reported to facilitate synaptic plasticity and promote neurogenesis, effects that have been associated with improved cognitive performance in experimental models involving N-methyl-D-aspartate (NMDA) receptor antagonists [25]. Moreover, studies indicate that CLZ modulates cholinergic tone by increasing ACh and DA levels in the medial prefrontal cortex and ventral hippocampus, aligning with improved attention and memory [26].
Although some findings point to potential neurotoxicity, the overall body of evidence supports its ability to reduce oxidative stress and apoptosis under specific conditions [27]. Complementing these results, recent molecular dynamics simulations from our laboratory revealed strong binding affinity of CLZ for 5-LOX, COX-2, AChE, and BuChE, with moderate activity at 15-LOX, suggesting a role in modulating neuroinflammatory and neurodegenerative pathways. These in silico findings were validated in biological assays, where CLZ treatment downregulated AChE, 5-LOX, COX-2, TNF-α, NF-κB, IL-6, Caspase-3, and MDA, while augmenting anti-inflammatory markers TGF-β1 and IL-10 [28].
However, despite these advances, the neuroprotective and anti-inflammatory effects of CLZ reported in LPS- and NMDA antagonist–based models have mostly been examined through isolated molecular pathways or limited biochemical endpoints, often without direct linkage to cognitive outcomes. To address this gap, the present study integrates behavioral assessment of multiple cognitive domains with a comprehensive, multi-pathway molecular analysis, including cholinergic function, GSK-3β, DPP-4, oxidative stress, and apoptotic signaling, within a single LPS-induced neurotoxicity framework. This integrative approach enables functional correlation between molecular modulation and cognitive recovery, thereby extending previous findings beyond confirmation of individual pathways.
2. Materials and Methods
2.1. Materials
All reagents utilized in this investigation were of analytical grade. CLZ and LPS (Escherichia coli O111:B4) were procured from Sigma-Aldrich (St. Louis, MO, USA). A 0.09% (w/v) normal saline solution served as the vehicle for drug dissolution and administration. Rat-specific ELISA kits used for the measurement of selected mechanistic biomarkers were sourced from MyBioSource (San Diego, CA, USA).
2.2. Animals
Adult male Sprague–Dawley rats (3–4 months of age; 180–200 g) were sourced from the Animal Facility, College of Pharmacy, Qassim University. Thirty animals were allocated at random into five treatment groups, with six rats assigned to each group. All animal-related procedures were reviewed and approved by the Committee of Health Research Ethics at Qassim University (Project No. 23-24-18). The experimental work followed the ARRIVE 2.0 guidelines, with particular attention to the Essential 10 items to promote rigor and transparency in in vivo research [29]. Animals were maintained under standardized conditions (12 h light/dark cycle) with free access to food and water for the entire study duration. To reduce handling-related stress and ensure environmental adaptation, rats underwent a one-week acclimatization period before the start of experimental interventions.
2.3. Treatment Schedule
As outlined earlier, the study comprised five experimental groups. The control group (CON; Group 1) received the vehicle alone, consisting of normal saline (NS; 0.1 mL/100 g, p.o.) administered daily from days 1 to 30. To ensure uniform handling and injection procedures, these animals also received intraperitoneal injections of NS (1 mg/kg) on days 22–25. Group 2 (CZ10) was treated with clozapine (CLZ; 10 mg/kg, p.o.) throughout the 30-day period and similarly received NS injections (1 mg/kg, i.p.) on days 22–25. Group 3 (LPS) served as the neuroinflammatory challenge group and was administered oral NS daily for 30 days, as well as intraperitoneal injections of lipopolysaccharide (LPS; 1 mg/kg) on days 22–25 to induce neurotoxic and inflammatory changes. Groups 4 and 5 (L+CZ5 and L+CZ10) received oral CLZ at doses of 5 mg/kg and 10 mg/kg, respectively, for the entire treatment duration and were exposed to LPS injections on days 22–25 in the same manner as the LPS-only group. The doses of CLZ and LPS were selected based on previously validated experimental data [28,30]. Behavioral evaluations were conducted during the final phase of the experiment. Cognitive performance was evaluated across three behavioral paradigms. Learning acquisition and retention were measured in the elevated plus-maze (EPM) on days 26 and 27, respectively. Recognition memory was assessed using the novel object recognition (NOR) task on days 28 and 29, whereas spatial working memory was tested in the Y-maze on day 30. After completion of the behavioral experiments, the animals were humanely euthanized, and whole-brain samples were collected for subsequent ELISA-based biochemical analyses (Figure 1).
Figure 1.
Schematic illustration of the experimental workflow and assessment schedule. Animals received oral treatments for a continuous 30-day period. Neuroinflammatory insult was produced by administering LPS (1 mg/kg, i.p.) on days 22–25. Cognitive performance was evaluated from days 26 to 30 using a series of behavioral tasks: elevated plus-maze (EPM), novel object recognition (NOR), and Y-maze. Following completion of behavioral testing on day 30, brain tissues were collected for subsequent ELISA-based biochemical analyses.
2.4. Maze Models
2.4.1. EPM Test
Learning and memory functions in rats were evaluated using the EPM, following established methodologies [30,31]. The maze comprised four arms arranged in a cross configuration, consisting of two open arms (50 × 10 cm) and two closed arms (50 × 10 × 40 cm), and was positioned 50 cm above the ground level. Rats naturally avoid open and elevated environments and therefore show a preference for enclosed arms, a behavior that serves as the basis for memory assessment in this model. Cognitive performance was quantified by measuring transfer latency (TL), defined as “the time taken by an animal to move from an open arm into one of the closed arms”. The EPM protocol included two sessions: an acquisition (training) session and a retention session. On day 26 (acquisition phase), rats were placed at the end of an open arm and permitted to freely explore the apparatus for 2 min; the time taken to enter a closed arm (transfer latency) was recorded, with a maximum limit of 90 s. The retention phase was conducted 24 h later (day 27) using the same procedure. TL values recorded during the first session were considered indicative of learning ability, while values obtained during the second session reflected memory retention.
2.4.2. NOR Test
Recognition memory in rats was evaluated using the NOR paradigm, which exploits the innate tendency of rodents to preferentially investigate unfamiliar objects over familiar ones [30,31]. The task was performed in a wooden arena (80 × 60 × 40 cm) containing objects of comparable dimensions but distinct geometrical shapes. Two identical cylindrical objects were designated as familiar objects (FO1 and FO2), whereas a rectangular object was used as the novel object (NO). The NOR procedure comprised three consecutive stages. On day 28, the animals underwent a habituation session in which each rat was allowed to explore the empty arena freely for 5 min to acclimate to the testing environment. Twenty-four hours later (day 29), the training phase was conducted by placing rats in the arena containing two identical FOs positioned symmetrically; exploration was permitted for 5 min. Following a 3 h retention interval, the test phase was initiated, during which one of the FOs was replaced with the NO, and the rats were again allowed a 5 min exploration period. Object exploration was recorded using a webcam, and the time spent exploring the familiar (ETFO) and novel (ETNO) objects was quantified. Exploration was defined as “the rat orienting its nose toward an object within a distance of ≤2 cm or actively sniffing the object”. Recognition memory performance was expressed as the discrimination index (DI%), calculated using the following equation:
DI% = [(ETNO − ETFO))/((ETNO + ETFO)] × 100
2.4.3. Y-Maze Test
The Y-maze paradigm was employed to assess spatial working memory and exploratory behavior in rats, capitalizing on their inherent preference for novel environments [30,31]. The apparatus consisted of three identical wooden arms (50 × 10 × 30 cm) arranged symmetrically at 120° angles from one another. Distinct visual cues were positioned at the terminal end of each arm to facilitate spatial discrimination. The test was performed on day 30 and comprised two consecutive sessions. During the initial training session, one arm, designated as the novel arm, was closed, while rats were allowed unrestricted exploration of the remaining two arms for 5 min. After a 3 h retention interval, the previously blocked arm was opened, and the animals were permitted to explore all three arms freely for an additional 5 min during the test session. Throughout the test phase, the number of entries into the known arms (NEKA) and the novel arm (NENA) was recorded, along with the duration spent in each arm. Spatial memory performance was expressed as the percentage of total exploration time spent in the novel arm (TSNA%), calculated relative to overall arm exploration time.
2.5. Brain Tissue Isolation and Homogenate Preparation
At the conclusion of the experimental protocol on day 30, upon completion of all behavioral evaluations, and following anesthesia with ketamine (100 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.), the animals were humanely euthanized via cervical dislocation. The intact brain was immediately excised, gently washed with chilled normal saline to eliminate residual blood, and processed for biochemical investigations. Whole-brain samples were gently homogenized in chilled phosphate-buffered saline (PBS; pH 7.4) to preserve biochemical integrity. The homogenates were then subjected to centrifugation at 4000 rpm for 10 min at 4 °C to separate the supernatant. Collected supernatants were aliquoted and preserved at −80 °C until use in ELISA measurements of selected biochemical parameters. Quantification of total protein in the homogenized brain samples was carried out using the biuret colorimetric technique.
2.6. ELISA Analysis
Biochemical parameters were quantified using rat-specific ELISA kits obtained from MyBioSource Inc. (San Diego, CA, USA). Prior to analysis, brain homogenate supernatants were equilibrated to room temperature. Optical density was recorded at a wavelength of 450 nm using a microplate reader, and analyte concentrations were determined by interpolation from standard curves prepared individually for each assay.
2.6.1. Cholinergic Marker
ACh (catalog no. MBS8820077) concentrations were determined to evaluate cholinergic activity using a competitive immunoassay approach. In brief, calibration standards and brain homogenate samples were dispensed into antibody-coated microplate wells, followed by the addition of enzyme-linked conjugate and assay-specific antibodies. After the incubation period, unbound components were removed through washing steps, and chromogenic substrate was then applied. The enzymatic reaction was subsequently halted by adding stop solution. The resulting color signal exhibited an inverse relationship with the ACh content present in the samples.
2.6.2. Neurodegeneration-Related Enzymes
Sandwich immunoassay kits were employed to quantify the levels of GSK-3β (catalog no. MBS766198), BACE-1 (catalog no. MBS1605521), and DPP-4 (catalog no. MBS163603) in brain homogenate samples. Standards and samples were incubated in antibody-coated wells, followed by biotinylated detection antibodies and streptavidin-HRP conjugate. After substrate addition, absorbance values were recorded and enzyme concentrations were calculated from standard curves.
2.6.3. Oxidative Stress Parameters
Oxidative stress status was evaluated by estimating LPO (catalog no. MBS8807819), catalase (catalog no. MBS2704433), and GSH (catalog no. MBS8822238) levels. Each parameter was quantified using ELISA-based methods following kit-specific instructions. These assays provided an index of lipid peroxidation and antioxidant defense capacity in brain tissue.
2.6.4. Apoptotic Markers
Neuronal apoptosis was assessed by determining levels of Bcl-2 (catalog no. MBS452319), Bax (catalog no. MBS2024395), and cleaved Caspase-3 (catalog no. MBS1605634). Sandwich ELISA techniques were employed, involving antigen capture, detection antibody binding, and enzyme-mediated color development. Concentrations were derived from standard curves and expressed relative to total protein content.
2.7. Statistical Analysis
All values are presented as mean ± SEM. Statistical comparisons were carried out in GraphPad Prism (9.5.0; GraphPad Software Inc., San Diego, CA, USA) using one-way ANOVA followed by Tukey–Kramer multiple-comparison testing. Significance was accepted at p < 0.05.
3. Results
3.1. CLZ Improves Learning and Memory Performance in LPS-Induced Rats in the EPM Test
Performance in the EPM revealed significant group-dependent effects on learning and memory following LPS exposure and CLZ treatment 1 (Figure 2). One-way ANOVA demonstrated a significant difference (F(4,25) = 8.457, p = 0.0002) among groups during the acquisition phase on test day 1 (Figure 2A). Rats in the LPS group showed a marked increase in TL compared with the control group (p < 0.01), indicating impaired learning ability. In contrast, rats treated with CLZ alone (CZ10) exhibited TL values comparable to controls, suggesting that CLZ did not adversely affect learning. Notably, co-administration of CLZ significantly attenuated the LPS-induced learning deficit, as evidenced by a pronounced reduction in TL in the L+CZ10 group compared with the LPS group (p < 0.001).
Figure 2.
Effects of CLZ and LPS on EPM performance. (A) Transfer latency (TL) measured on test day 1, reflecting learning acquisition. (B) TL measured on test day 2, reflecting memory retention. Mean ± SEM (n = 6). One-way ANOVA tests, followed by Tukey–Kramer post hoc comparisons, revealed significant group differences on test day 1-F(4,25) = 8.457, p = 0.0002 and test day 2-F(4,25) = 11.13, p < 0.0001. Significance levels are indicated as: ## p < 0.01 and ### p < 0.001 in relation to CON; ** p < 0.01 and *** p < 0.001 in relation to CZ10; $$ p < 0.01 and $$$ p < 0.001 in relation to LPS.
A similar pattern was observed during the retention phase on test day 2, with one-way ANOVA revealing a robust group effect (F(4,25) = 11.13, p < 0.0001) (Figure 2B). Rats receiving LPS alone displayed significantly prolonged TL relative to controls (p < 0.001), reflecting impaired memory retention. Treatment with CLZ significantly reversed this deficit, as demonstrated by reduced TL values in the L+CZ10 group compared with the LPS group (p < 0.01). The higher dose of CLZ (10 mg/kg) produced a more pronounced improvement, bringing TL values closer to those observed in the control animals. Collectively, the findings indicate that CLZ counteracts the detrimental effects of LPS on learning acquisition and memory retention, leading to a clear improvement in EPM performance.
3.2. CLZ Improves Recognition Memory in LPS-Induced Rats in the NOR Test
Performance in the NOR test demonstrated significant alterations in recognition memory following LPS exposure and CLZ treatment (Figure 3). One-way ANOVA revealed significant group effects for ETFO (F(4,25) = 14.55, p < 0.0001), ETNO (F(4,25) = 25.56, p < 0.0001), and DI% (F(4,25) = 4.095, p = 0.0109).
Figure 3.
Effects of CLZ and LPS on performance in the NOR test. (A) Exploration time of familiar object (ETFO), indicative of retention behavior. (B) Exploration time of novel object (ETNO) and (C) discrimination index (DI)%, reflecting recognition memory performance. Mean ± SEM (n = 6). One-way ANOVA, followed by Tukey–Kramer multiple comparison testing, exposed significant group effects for ETFO-F(4,25) = 14.55, p < 0.0001, ETNO-F(4,25) = 25.56, p < 0.0001, and DI%-F(4,25) = 4.095, p = 0.0109. Significance is denoted as: ### p < 0.001 in relation to CON; * p < 0.01 and *** p < 0.001 in relation to CZ10; $ p < 0.05, $$ p < 0.01 and $$$ p < 0.001 in relation to LPS.
Compared with the controls, rats receiving LPS demonstrated a pronounced decrease in ETFO (p < 0.001), suggesting a deficit in retaining familiarity with the previously explored object (Figure 3A). In contrast, CLZ-treated rats (CZ10) displayed ETFO values comparable to the controls, suggesting that CLZ did not adversely affect memory retention. Co-administration of CLZ significantly attenuated the LPS-induced deficit, as evidenced by increased ETFO values in both L+CZ5 (p < 0.01) and L+CZ10 (p < 0.001) groups compared with the LPS group, with the higher dose showing a more pronounced effect.
Similarly, ETNO was significantly reduced in the LPS group relative to the controls (p < 0.001), reflecting impaired novelty recognition (Figure 3B). Treatment with CLZ effectively restored ETNO, with both L+CZ5 and L+CZ10 groups exhibiting significantly higher exploration of the NO (p < 0.001) compared with LPS-treated rats. Notably, CLZ alone produced a modest increase in ETNO relative to controls, consistent with preserved or enhanced recognition memory.
The DI further supported these findings (Figure 3C). LPS administration significantly decreased DI% compared with the control animals (p < 0.05), confirming disruption of recognition memory. CLZ co-treatment significantly improved DI%, with values in the L+CZ10 group approaching those observed in the control and CZ10 groups (p < 0.05). Collectively, these outcomes illustrate that CLZ efficiently counteracts LPS-induced deficits in recognition memory, as reflected by restored object exploration patterns and improved discrimination performance in the NOR task.
3.3. CLZ Improves Spatial Working Memory and Exploratory Behavior in LPS-Induced Rats in the Y-Maze Test
Performance in the Y-maze test revealed significant alterations in spatial working memory and exploratory behavior following LPS administration and CLZ treatment (Figure 4). One-way ANOVA confirmed significant group effects for the NEKA (F(4,25) = 7.371, p = 0.0005), NENA (F(4,25) = 4.103, p = 0.0105), and TSNA% (F(4,25) = 4.374, p = 0.0081).
Figure 4.
Effects of CLZ and LPS on performance in the Y-maze test. (A) Number of entries into the known arms (NEKA), reflecting general exploratory behavior and familiarity with previously accessed arms. (B) Number of entries into novel arm (NENA) and (C) Time spent in the novel arm (TSNA)%, indicating novelty preference and spatial working (recognition) memory. Mean ± SEM (n = 6). One-way ANOVA, followed by Tukey–Kramer post hoc multiple comparisons, revealed significant group effects for NEKA-F(4,25) = 7.371, p = 0.0005, NENA-F(4,25) = 4.103, p = 0.0105, and TSNA%-F(4,25) = 4.374, p = 0.0081. Statistical significance is indicated as: # p < 0.05 and ### p < 0.001 in relation to CON; * p < 0.05 and ** p < 0.01 in relation to CZ10; $ p < 0.05 in relation to LPS.
Rats exposed to LPS alone demonstrated a substantial reduction in NEKA compared with the control animals (p < 0.001), indicating disrupted exploratory behavior and altered familiarity processing (Figure 4A). In contrast, rats treated with CLZ alone (CZ10) showed NEKA values comparable to the controls, suggesting preserved exploratory activity. Co-treatment with CLZ significantly ameliorated the LPS-induced reduction in NEKA, with the L+CZ10 group showing a notable increase relative to the LPS group (p < 0.05).
Similarly, NENA was markedly reduced in the LPS-treated group compared with the controls (p < 0.05), reflecting impaired novelty-seeking behavior and compromised spatial working memory (Figure 4B). CLZ administration significantly reversed this effect, as evidenced by increased NENA values in both the L+CZ5 and L+CZ10 groups relative to LPS-treated rats. The upper dose of CLZ (10 mg/kg) produced a more pronounced improvement, restoring NENA values toward control levels.
Consistent with these findings, TSNA% was markedly reduced in the LPS group relative to the controls (p < 0.05), reflecting compromised spatial recognition memory (Figure 4C). CLZ co-treatment significantly increased TSNA%, particularly in the L+CZ10 group, indicating improved preference for the novel arm and enhanced spatial working memory. Overall, the Y-maze outcomes show that CLZ counteracts the deficits in exploratory activity and spatial working memory produced by LPS exposure.
3.4. CLZ Restores Cholinergic Function in LPS-Induced Rats
Rats administered LPS alone exhibited a pronounced reduction in ACh levels compared with the control group (p < 0.01), indicating marked cholinergic dysfunction induced by systemic inflammation (Figure 5). In contrast, CLZ-treated rats (CZ10) showed ACh concentrations comparable to control values, suggesting that CLZ alone did not alter baseline cholinergic activity. Importantly, co-administration of CLZ significantly attenuated the LPS-induced decline in ACh levels. Both L+CZ5 and L+CZ10 groups displayed significantly higher ACh levels compared with the LPS group, with the higher CLZ dose producing a more robust restoration (p < 0.001). In the L+CZ10 group, ACh levels approached those observed in control animals. Collectively, these findings demonstrate that CLZ effectively counteracts LPS-induced cholinergic deficits in the rat brain, supporting its role in preserving neurotransmitter systems critical for learning and memory.
Figure 5.
Acetylcholine (ACh) levels in rat brain following CLZ and LPS treatment. Mean ± SEM (n = 6). One-way ANOVA, followed by Tukey–Kramer post hoc multiple comparisons, revealed a significant overall group effect F(4,25) = 12.08, p < 0.000. Significance is denoted as: ## p < 0.01 in relation to CON; *** p < 0.001 in relation to CZ10; $ p < 0.05 and $$$ p < 0.001 in relation to LPS.
3.5. CLZ Attenuates LPS-Induced Alterations in Neurodegeneration-Associated Enzymes
Analysis of neurodegeneration-related enzymes revealed significant dysregulation following LPS administration, which was markedly ameliorated by CLZ treatment (Figure 6). One-way ANOVA demonstrated significant overall group effects for GSK-3β (F(4,25) = 11.41, p < 0.0001), BACE-1 (F(4,25) = 14.64, p < 0.0001), and DPP-4 (F(4,25) = 9.685, p < 0.0001).
Figure 6.
Effects of CLZ and LPS on neurodegeneration-associated enzymes in rat brain tissue. (A) Glycogen synthase kinase-3 beta (GSK-3β), (B) β-site amyloid precursor protein cleaving enzyme-1 (BACE-1), and (C) Dipeptidyl peptidase-4 (DPP-4). Mean ± SEM (n = 6). One-way ANOVA, followed by Tukey–Kramer post hoc multiple comparisons, displayed significant group effects for GSK-3β-F(4,25) = 11.41, p < 0.0001, BACE-1-F(4,25) = 14.64, p < 0.0001, and DPP-4-F(4,25) = 9.685, p < 0.0001. Significance is indicated as: # p < 0.05, ## p < 0.05 and ### p < 0.001 in relation to CON; * p < 0.01, ** p < 0.01, and *** p < 0.001 in relation to CZ10; $$ p < 0.01 and $$$ p < 0.001 in relation to LPS.
Rats exposed to LPS alone exhibited a pronounced elevation in GSK-3β levels compared with the control animals (p < 0.001), indicating enhanced kinase activity associated with neurodegenerative signaling (Figure 6A). In contrast, CLZ-treated rats (CZ10) displayed GSK-3β levels comparable to controls, suggesting no intrinsic effect of CLZ on basal enzyme activity. Importantly, CLZ co-administration significantly reduced LPS-induced GSK-3β elevation, with both L+CZ5 (p < 0.01) and L+CZ10 (p < 0.001) groups showing markedly lower levels associated with the LPS rats, and the higher dose producing a considerable normalization outcome.
A similar pattern was observed for BACE-1 expression (Figure 6B). LPS administration significantly increased BACE-1 levels relative to the controls (p < 0.001), reflecting enhanced amyloidogenic processing. CLZ alone had no significant effect on BACE-1 expression. Co-treatment with CLZ showed a modest downward trend in BACE-1 levels matched with the LPS group; however, these changes were not statistically significant.
DPP-4 levels were also considerably raised in the LPS group compared with the controls (p < 0.001), indicating activation of pathways linked to neuroinflammation and metabolic dysregulation (Figure 6C). While CLZ alone did not significantly affect DPP-4 expression, co-administration of CLZ significantly reduced DPP-4 levels in LPS-challenged rats, with the higher dose again providing more pronounced protection.
Collectively, these findings demonstrate that LPS induces robust upregulation of key enzymes implicated in neurodegenerative processes, whereas CLZ effectively counteracts these alterations without disrupting basal enzyme expression, supporting its modulatory role against inflammation-driven neurodegeneration.
3.6. CLZ Attenuates LPS-Induced Oxidative Stress in Rat Brain
Valuation of oxidative stress–related parameters revealed marked redox imbalance following LPS exposure, which was significantly mitigated by CLZ treatment (Figure 7). One-way ANOVA demonstrated significant group effects for LPO (F(4,25) = 13.53, p < 0.0001), catalase (F(4,25) = 14.96, p < 0.0001), and GSH (F(4,25) = 8.469, p = 0.0002).
Figure 7.
Effects of CLZ and LPS on oxidative stress–related parameters in rat brain tissue. (A) Lipid peroxidation (LPO), (B) Catalase, and (C) Reduced glutathione (GSH) levels. Mean ± SEM (n = 6). One-way ANOVA, followed by Tukey–Kramer post hoc multiple comparisons, revealed significant group differences for LPO-F(4,25) = 13.53, p < 0.0001, catalase -F(4,25) = 14.96, p < 0.0001, and GSH-F(4,25) = 8.469, p = 0.0002. Significance levels are denoted as: ## p < 0.05 and ### p < 0.001 in relation to CON; *** p < 0.001 in relation to CZ10; $ p < 0.05, $$ p < 0.01, and $$$ p < 0.001 in relation to LPS.
LPS administration resulted in a pronounced upsurge in LPO levels compared with the control rats (p < 0.001), indicating enhanced oxidative damage to membrane lipids (Figure 7A). CLZ treatment alone (CZ10) did not significantly alter LPO levels relative to the controls. Importantly, co-treatment with CLZ significantly reduced LPS-induced LPO elevation, with both L+CZ5 (p < 0.01) and L+CZ10 (p < 0.001) groups showing lower LPO levels than the LPS group, and the higher dose producing a more robust reduction.
In parallel, catalase activity was pointedly diminished in LPS-treated rats in relation to the controls (p < 0.01), reflecting compromised antioxidant defense (Figure 7B). CLZ alone maintained catalase activity at levels comparable to the controls. Notably, CLZ co-administration significantly restored catalase activity in LPS-challenged rats, with both doses improving enzyme activity (p < 0.001) relative to the LPS group and both doses showing greater efficacy.
Similarly, GSH levels were markedly reduced following LPS exposure (p < 0.001 vs. control), confirming depletion of endogenous antioxidant reserves (Figure 7C). While CLZ alone did not significantly affect basal GSH levels, CLZ co-treatment significantly increased GSH concentrations in LPS-treated rats, particularly in the L+CZ10 group (p < 0.05), indicating effective restoration of redox balance.
Collectively, these findings demonstrate that LPS induces substantial oxidative stress in the brain, characterized by increased LPO and impaired antioxidant defenses, whereas CLZ effectively counteracts these alterations and preserves redox homeostasis under inflammatory conditions.
3.7. CLZ Attenuates LPS-Induced Neuronal Apoptosis in Rat Brain
Evaluation of apoptosis-related proteins revealed a marked activation of pro-apoptotic signaling following LPS exposure, which was significantly mitigated by CLZ treatment (Figure 8). One-way ANOVA demonstrated significant overall group effects for Bcl-2 (F(4,25) = 13.16, p < 0.0001), Bax (F(4,25) = 9.020, p = 0.0001), and c-Caspase-3 (F(4,25) = 11.64, p < 0.0001).
Figure 8.
Effects of CLZ and LPS on apoptosis-related protein expression in rat brain tissue. (A) B-Cell lymphoma-2 (Bcl-2), (B) Bcl-2-associated X protein (Bax), and (C) Cleaved Caspase-3 (c-Caspase-3). Mean ± SEM (n = 6). One-way ANOVA, followed by Tukey–Kramer post hoc multiple comparisons, revealed significant group effects for Bcl-2-F(4,25) = 13.16, p < 0.0001, Bax-F(4,25) = 9.020, p = 0.0001, and c-Caspase-3-F(4,25) = 11.64, p < 0.0001. Significance is denoted as: # p < 0.05 and ### p < 0.001 in relation to CON; * p < 0.05, ** p < 0.01, and *** p < 0.001 in relation to CZ10; $ p < 0.05, $$ p < 0.01, and $$$ p < 0.001 in relation to LPS.
Rats challenged with LPS alone showed a substantial reduction in the anti-apoptotic protein Bcl-2 relative to the control animals (p < 0.001), representing diminished neuronal survival signaling (Figure 8A). CLZ treatment alone (CZ10) maintained Bcl-2 levels comparable to the controls. Importantly, CLZ co-administration significantly restored Bcl-2 expression in LPS-treated rats, with both the L+CZ5 and L+CZ10 groups showing higher Bcl-2 levels compared to the LPS group, and only the higher dose producing a more pronounced recovery (p < 0.01).
Conversely, LPS administration resulted in a significant elevation of Bax levels compared with the controls (p < 0.001), reflecting activation of pro-apoptotic pathways (Figure 8B). CLZ alone did not significantly alter Bax expression. Co-treatment with CLZ significantly reduced Bax levels in LPS-challenged rats, with both doses producing attenuation of the LPS-induced increase, and considerable normalization observed at 10 mg/kg (p < 0.05).
Consistent with these findings, c-Caspase-3 levels were markedly increased in the LPS group relative to the controls (p < 0.001), indicating executioner Caspase activation and progression of apoptosis (Figure 8C). CLZ co-treatment significantly suppressed this increase (p < 0.001), with both the L+CZ5 and L+CZ10 groups showing reduced c-Caspase-3 levels compared with the LPS group, and the higher dose again conferring stronger protection. CLZ alone did not significantly affect basal c-Caspase-3 expression.
Overall, these results demonstrate that LPS induces a pronounced shift toward pro-apoptotic signaling in the rat brain, whereas CLZ effectively counteracts these changes by restoring anti-apoptotic defenses and suppressing apoptotic execution, supporting its neuroprotective role under inflammatory conditions.
4. Discussion
Cognitive impairment is a central feature of both neuropsychiatric and neurodegenerative disorders, including schizophrenia and dementia, where neuroinflammation, oxidative stress, and neuronal apoptosis converge to disrupt synaptic and neurotransmitter homeostasis [1,4]. Our earlier work demonstrated the potential neuroprotective properties of CLZ through molecular docking and molecular dynamics analyses, which were further supported by complementary biological findings [28]. Building on those observations, the present study shows that systemic LPS exposure leads to pronounced impairments in learning, memory, and exploratory behavior, together with substantial cholinergic disruption, alterations in neurodegeneration-related enzymes, enhanced oxidative stress, and activation of apoptotic signaling pathways in the rat brain. Importantly, continuing CLZ treatment significantly mitigated these behavioral and molecular alterations, highlighting its neuroprotective potential beyond antipsychotic efficacy.
The findings from the EPM revealed that LPS administration produced a clear disruption in learning and retention performance, as reflected by the significant increase in TL during both the acquisition and retention trials. In the present protocol, TL is commonly interpreted as an index of learning and memory retention; however, it should be acknowledged that EPM performance may also be influenced by anxiety-related behavior. Consistent with previous reports, LPS-induced neurobehavioral alterations are frequently associated with impairments in task acquisition and memory retrieval in rodent models of inflammation-associated cognitive dysfunction [32,33]. In contrast, rats that received CLZ alone performed similarly to the control animals, indicating that CLZ did not adversely influence baseline learning ability. Importantly, co-treatment with CLZ markedly improved EPM performance in LPS-exposed rats, as evidenced by the significant reduction in TL across both testing sessions. This pattern suggests that CLZ was able to counteract the learning and memory deficits induced by LPS, which aligns with earlier behavioral findings reporting preserved task performance in CLZ-treated animals across memory-dependent paradigms [34]. Overall, the EPM outcomes in the present study demonstrate that LPS impairs learning and retention, whereas CLZ treatment is associated with a measurable improvement in task performance under conditions of inflammatory challenge.
In the NOR task, LPS exposure produced a clear disruption in recognition memory, as indicated by the reduction in exploration time directed toward the NO and the decline in DI values. This behavioral pattern is consistent with earlier findings showing that inflammatory challenge interferes with novelty preference and object recognition performance in rodents, reflecting difficulty in distinguishing previously encountered objects from new ones [35]. Rats treated with CLZ alone performed comparably to the controls, indicating that CLZ did not adversely affect baseline recognition ability. Notably, CLZ co-treatment improved recognition performance in LPS-challenged rats, as evidenced by increased exploration of the NO and a corresponding enhancement in DI compared with the LPS group. Consistent with these findings, earlier experimental studies also showed that CLZ enhances recognition-based performance in NOR tasks across various neurotoxicity-induced models, including ketamine- and MK-801-challenged rodents, where it has been reported to attenuate memory disturbances and support cognitive function [36,37,38]. Overall, the NOR outcomes from the present investigation demonstrate that LPS impairs recognition memory, whereas CLZ treatment is associated with a clear improvement in task performance within this behavioral paradigm.
In the Y-maze task, LPS administration produced a clear disruption in spatial working memory, as evidenced by the reduction in entries into the novel arm and the lower percentage of time spent exploring it. This attenuation of novelty-directed exploration is consistent with earlier reports showing that inflammatory or stress-related challenges impair spontaneous alternation and novelty preference behaviors in rodents, reflecting difficulty in updating and retaining spatial information [39]. Animals treated with CLZ alone performed similarly to the controls, indicating that CLZ does not adversely influence baseline exploratory activity or memory-related behavior in this paradigm. In contrast, CLZ co-treatment improved task performance in LPS-exposed rats, as revealed by the greater frequency of novel-arm entries and the increased proportion of time allocated to this arm compared with the LPS group. These findings are in line with previous behavioral evidence showing that CLZ administration can preserve or enhance performance in spatial memory–dependent tasks under experimental challenge conditions [40]. Taken together, the present Y-maze results indicate that LPS produces measurable impairments in spatial working memory, whereas CLZ treatment is associated with a clear improvement in behavioral performance within this model.
The cholinergic system plays a central role in learning, attention, and memory, particularly through basal forebrain projections to the hippocampus and cortex, where ACh modulates synaptic plasticity and memory encoding [41]. In the present study, LPS administration resulted in a significant reduction in brain ACh levels, consistent with earlier reports demonstrating that neuroinflammatory states suppress cholinergic neurotransmission and contribute to cognitive impairment in both dementia- and schizophrenia-related pathology [42,43]. Co-treatment with CLZ restored ACh concentrations in LPS-challenged rats, whereas CLZ alone did not alter basal levels, suggesting that its effect reflects preservation of cholinergic tone under inflammatory stress rather than nonspecific enhancement of cholinergic signaling. The recovery of ACh signaling is likely to contribute to the improvement in recognition and spatial memory observed in the behavioral tasks. These findings align with previous evidence indicating that CLZ can modulate cortical–hippocampal neurotransmission and support cognitive function in pathological or neuroinflammatory conditions [26,40]. Collectively, the data point to cholinergic stabilization as a likely factor in the cognition-enhancing effects of CLZ under LPS-induced neurobehavioral stress.
GSK-3β is a multifunctional kinase that plays a central role in synaptic regulation, cytoskeletal stability, and neuronal survival, and its pathological overactivation has been widely implicated in cognitive impairment and neurodegenerative processes [44]. Elevated GSK-3β activity promotes tau phosphorylation, synaptic dysfunction, and neuronal vulnerability, which are changes closely associated with memory decline across psychiatric and neurodegenerative disorders [44,45]. In the present study, LPS exposure significantly increased brain GSK-3β levels, consistent with evidence that inflammatory signaling enhances GSK-3β activation and contributes to neurobehavioral deficits [46]. CLZ co-treatment attenuated this elevation, suggesting a modulatory influence on GSK-3β-linked neurodegenerative pathways. Such attenuation may be relevant to the observed improvements in learning and memory performance, as normalization of GSK-3β signaling has been associated with better cognitive outcomes in experimental models. Taken together, these findings support the view that partial suppression of GSK-3β activity may represent one of the neuroprotective components of CLZ action under inflammatory challenge.
BACE-1 serves as the catalytic trigger for the β-secretase step in amyloid precursor protein (APP) processing, and increases in its activity are widely associated with enhanced Aβ generation and subsequent deterioration of synaptic function and cognition [47]. Evidence from experimental and clinical studies indicates that neuroinflammation is one of the conditions that can drive BACE-1 upregulation, reinforcing amyloidogenic signaling within vulnerable neural circuits [48]. In the present work, LPS exposure produced a rise in BACE-1 levels, a finding that is consistent with this inflammation-linked regulatory pattern. Importantly, CLZ co-treatment did not significantly reverse the LPS-induced increase in BACE-1 expression, indicating that CLZ does not exert a direct modulatory effect on β-secretase–mediated amyloidogenic processing under the present experimental conditions. Therefore, any behavioral improvements observed in CLZ-treated animals are unlikely to be attributable to direct regulation of BACE-1 activity, but may instead reflect broader anti-inflammatory and antioxidant actions that indirectly preserve synaptic function in the context of inflammatory stress [49].
Beyond its classical metabolic functions, DPP-4 has gained attention as a regulator of neuroinflammatory and oxidative processes that influence neuronal health and cognitive performance [17]. Inflammatory and metabolic stressors are known to elevate DPP-4 activity, a shift that can amplify cytokine signaling, increase oxidative burden, and compromise synaptic function within cognition-relevant brain regions [50]. In the present study, LPS administration was accompanied by a rise in DPP-4 levels, consistent with the notion that systemic inflammation drives DPP-4-associated neurobiological disturbances. Interestingly, rats co-treated with CLZ displayed lower DPP-4 levels compared with the LPS group, indicating that CLZ may help temper this inflammatory-metabolic axis rather than allowing it to escalate unchecked. Although this effect may be indirect, the moderation of DPP-4 signaling could reduce downstream inflammatory stress and thereby support the cognitive improvements observed in CLZ-treated animals.
Oxidative stress represents a major pathogenic interface between neuroinflammation and neuronal injury, and is strongly activated following systemic LPS challenge [30]. In the present study, LPS exposure markedly increased LPO, reflecting excessive production of ROS and oxidation of membrane polyunsaturated fatty acids. LPO products such as MDA and 4-hydroxynonenal are known to alter membrane fluidity, disrupt ion-channel function, impair synaptic vesicle release, and trigger downstream inflammatory signaling cascades, thereby contributing to cognitive and behavioral dysfunction [51]. The rise in LPO observed here is consistent with evidence that microglial activation and mitochondrial ROS generation serve as major upstream sources of oxidative injury in LPS-exposed brain tissue [52]. Concurrently, LPS produced a marked reduction in endogenous antioxidant defenses, particularly catalase and GSH, indicating failure of the enzymatic and non-enzymatic redox buffering systems. Catalase plays a critical role in decomposing hydrogen peroxide into water and oxygen; suppression of catalase activity permits the accumulation of H2O2 and favors conversion to highly reactive hydroxyl radicals via Fenton chemistry, thereby amplifying oxidative damage to cellular macromolecules [53]. GSH functions as the principal intracellular redox buffer and cofactor for glutathione peroxidase, detoxifying peroxides and maintaining mitochondrial redox stability. Depletion of GSH is therefore associated with impaired mitochondrial respiration, increased lipid membrane susceptibility to oxidation, and a greater tendency toward apoptotic signaling under inflammatory stress [54]. These alterations collectively indicate a collapse of redox homeostasis in response to LPS-induced neuroinflammation, in agreement with prior studies in LPS-challenged brain models [55]. Co-administration of CLZ significantly reversed these oxidative disturbances, as demonstrated by the reduction in LPO together with restoration of catalase and GSH levels. This pattern suggests that CLZ not only limits ROS accumulation, potentially through the attenuation of microglial activation and mitochondrial oxidative output, but also reinforces endogenous antioxidant capacity by stabilizing enzymatic redox systems. Such protection is particularly relevant in the brain, where high lipid density, elevated oxygen consumption, and relatively low basal antioxidant reserves render neurons highly vulnerable to oxidative injury. By re-establishing redox equilibrium, CLZ likely prevents secondary structural and molecular damage to neuronal membranes, proteins, and nucleic acids, thereby helping to preserve neuronal integrity and supporting improved cognitive performance under inflammatory challenge [30].
Apoptotic dysregulation represents a major downstream consequence of neuroinflammation and oxidative stress, and is strongly implicated in neuronal loss and cognitive impairment [56]. In the present study, LPS exposure produced a characteristic pro-apoptotic shift in brain tissue, as evidenced by reduced Bcl-2 levels together with increased expression of Bax and c-Caspase-3. Bcl-2 functions as an anti-apoptotic mitochondrial protein that stabilizes the outer mitochondrial membrane and prevents cytochrome-c release; its reduction is therefore indicative of weakened intrinsic cell-survival signaling. In contrast, Bax promotes mitochondrial outer-membrane permeabilization and facilitates the release of apoptogenic factors that activate the Caspase cascade [57]. The concurrent rise in c-Caspase-3, a key executioner protease responsible for DNA fragmentation and structural dismantling of the neuron, confirms activation of the intrinsic apoptotic pathway [58]. This molecular profile is consistent with previous LPS-based neuroinflammation models, in which mitochondrial dysfunction, oxidative stress, and cytokine signaling converge to promote Bax upregulation, Bcl-2 suppression, and Caspase-3 activation, ultimately leading to neuronal loss and behavioral deficits [30]. Co-administration of CLZ reversed this pro-apoptotic pattern by restoring Bcl-2 expression while reducing Bax and c-Caspase-3 levels, indicating a shift toward a neuroprotective, anti-apoptotic state. This effect may reflect both indirect stabilization via attenuation of oxidative and inflammatory stress, and direct regulation of mitochondrial survival pathways. Preservation of Bcl-2-mediated mitochondrial integrity is particularly important in vulnerable hippocampal and cortical regions involved in memory processing, where apoptotic susceptibility contributes to cognitive deterioration [59]. By limiting Caspase-dependent neuronal degeneration, CLZ likely supports maintenance of neuronal viability and synaptic function, providing a mechanistic basis for the behavioral improvements observed in LPS-challenged rats [30].
Beyond schizophrenia, the consistent restoration of behavioral and biochemical indices toward control levels in both L+CZ5 and L+CZ10 groups raises the possibility that CLZ, or other atypical antipsychotics, may exert beneficial effects in conditions characterized by inflammation-associated cognitive dysfunction. Clinically, atypical antipsychotics are sometimes used off-label in neurodegenerative disorders such as AD, DLB, and Parkinson’s disease (PD), primarily for the management of psychosis and behavioral disturbances rather than for direct cognitive enhancement [60]. CLZ, along with quetiapine, has demonstrated efficacy for psychosis in PD and DLB at low doses, largely due to favorable motor side-effect profiles; however, its broader application in dementia remains limited by safety concerns, monitoring requirements, and the increased risk of adverse outcomes [61]. Accordingly, the present findings should be interpreted as preclinical mechanistic evidence, demonstrating that CLZ can counteract inflammation-driven cognitive deficits and neurodegenerative signaling, rather than as direct support for its routine clinical use in dementia. Future studies employing disease-specific neurodegeneration models will be required to assess translatability.
Several limitations of the present study should be acknowledged. First, systemic LPS administration represents a model of acute neuroinflammation, rather than the full pathophysiology of schizophrenia; therefore, the findings should be interpreted in the context of inflammation-associated cognitive dysfunction rather than schizophrenia pathology per se. Second, biochemical analyses were performed using whole-brain homogenates, which limits region-specific mechanistic interpretation, particularly for hippocampal- and prefrontal cortex–dependent behaviors assessed by the EPM, NOR, and Y-maze. Third, key signaling molecules were quantified by ELISA, reflecting total protein levels without information on activation state or cellular localization, which constrains pathway-level conclusions. In addition, although CLZ-alone-treated animals did not show overt behavioral impairment, formal locomotor or sedation assessments were not performed, and potential motor confounds cannot be fully excluded. Finally, while the CLZ doses used (5 and 10 mg/kg) are commonly employed in preclinical studies and are considered to produce pharmacologically relevant brain exposure, direct translational equivalence to clinical dosing remains approximate due to interspecies pharmacokinetic differences. Future studies incorporating region-specific analyses, phospho-specific signaling assessments, locomotor controls, disease-relevant models, and pharmacokinetic profiling will be essential to refine mechanistic understanding and translational relevance.
Although the present study demonstrates that CLZ improves cognitive performance and restores cholinergic balance in an LPS-induced neurotoxicity model, it does not examine the upstream molecular signaling pathways responsible for these effects. In particular, receptor-level mechanisms, downstream kinase signaling, and transcriptional regulation of cholinergic function were beyond the scope of this work. Moreover, given CLZ’s potent antioxidant and anti-inflammatory properties, the extent to which the observed restoration of ACh levels reflects direct cholinergic modulation versus indirect preservation secondary to reduced oxidative and inflammatory burden cannot be definitively determined. Similar considerations apply to other molecular markers examined, including GSK-3β, BACE-1, and DPP-4, as well as the associated behavioral outcomes. As no pathway-specific pharmacological blockade or genetic validation was performed, the mechanistic interpretations presented here are based on associative, pathway-level evidence rather than causal signaling activation. Future studies employing targeted pharmacological inhibitors, receptor antagonists, or genetic approaches will be essential to delineate the relative contributions of individual pathways underlying CLZ-mediated protection against inflammation-associated cognitive dysfunction.
5. Conclusions
In conclusion, the present study demonstrates that CLZ attenuates LPS-induced cognitive impairment through the integrated modulation of several neurobiological processes. CLZ preserved cholinergic neurotransmission, partially normalized alterations in neurodegeneration-associated enzymes, restored redox balance by reducing oxidative stress and enhancing antioxidant defense, and shifted apoptotic signaling toward a neuroprotective profile. The combined influence of these mechanisms suggests that the cognitive benefits of CLZ arise from a coordinated stabilization of neuronal function rather than from a single molecular pathway. Overall, these findings support a role for CLZ in modulating inflammation-associated cognitive dysfunction, rather than providing direct evidence of efficacy against schizophrenia pathology itself. These observations expand the understanding of CLZ beyond its established antipsychotic actions and highlight its potential relevance in conditions characterized by cognitive dysfunction and neuronal vulnerability. Further studies incorporating additional mechanistic endpoints, region-specific analyses, and extended treatment designs are warranted to clarify the scope, durability, and translational significance of these effects.
Author Contributions
Conceptualization, V.M.; methodology, V.M. and M.A.A.; software, V.M.; validation, V.M. and M.A.A.; formal analysis, V.M.; investigation, V.M. and M.A.A.; resources, V.M.; data curation, V.M. and M.A.A.; writing—original draft preparation, V.M. and M.A.A.; writing—review and editing, V.M.; visualization, V.M.; supervision, V.M.; project administration, V.M.; funding acquisition, V.M. All authors have read and agreed to the published version of the manuscript.
Funding
This research was funded by the Deanship of Graduate Studies and Scientific Research, Qassim University, Saudi Arabia, under the project number (QU-J-PG-2-2025-53795) during the academic year 1446 AH/2024 AD.
Institutional Review Board Statement
The animal study protocol was reviewed and approved by the Committee of Health Research Ethics, Deanship of Scientific Research, Qassim University (proposal No. 23-24-18; approval date: 09 February 2023). The study proposal was subsequently revised and approved for funding by the Deanship of Graduate Studies and Scientific Research under project No. QU-J-PG-2-2025-53795 (approval date: 26 January 2025). All experimental procedures were conducted in accordance with institutional ethical standards and complied with the ARRIVE 2.0 guidelines, with specific adherence to the Essential 10 recommendations to ensure standardized, transparent, and reproducible in vivo experimentation.
Informed Consent Statement
Not applicable.
Data Availability Statement
The data presented in this study are available from the corresponding author upon reasonable request. The data are not publicly available due to privacy issues.
Acknowledgments
The authors gratefully acknowledge Qassim University, represented by the Deanship of Graduate Studies and Scientific Research, on the financial support for this research under the number (QU-J-PG-2-2025-53795) during the academic year 1446 AH/2024 AD.
Conflicts of Interest
The authors declare no conflicts of interest.
Abbreviations
The following abbreviations are used in this manuscript:
| ACh | Acetylcholine |
| AChE | Acetylcholinesterase |
| AD | Alzheimer’s Disease |
| APP | Amyloid Precursor Protein |
| BACE-1 | β-Site Amyloid Precursor Protein–Cleaving Enzyme-1 |
| Bax | Bcl-2-Associated X Protein |
| Bcl-2 | B-Cell Lymphoma-2 |
| c-Caspase-3 | Cleaved Caspase-3 |
| CLZ/CZ | Clozapine |
| DLB | Dementia with Lewy Bodies |
| DI% | Discrimination Index Percentage |
| DPP-4 | Dipeptidyl Peptidase-4 |
| EPM | Elevated Plus-Maze |
| ETFO | Exploration Time of Familiar Object |
| ETNO | Exploration Time of Novel Object |
| GSH | Reduced Glutathione |
| GSK-3β | Glycogen Synthase Kinase-3 Beta |
| LPO | Lipid Peroxidation |
| LPS | Lipopolysaccharide |
| L+CZ5 | LPS + Clozapine 5 mg/kg group |
| L+CZ10 | LPS + Clozapine 10 mg/kg group |
| NEKA | Number of Entries into the Known Arms |
| NENA | Number of Entries into Novel Arm |
| NOR | Novel Object Recognition |
| PD | Parkinson’s Disease |
| TL | Transfer Latency |
| TSNA% | Percentage of Time Spent in the Novel Arm |
References
- Stevenson-Hoare, J.; Legge, S.E.; Simmonds, E.; Han, J.; Owen, M.J.; O’Donovan, M.; Kirov, G.; Escott-Price, V. Severe psychiatric disorders are associated with increased risk of dementia. BMJ Ment. Health 2024, 27, e301097. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Sami, M.; Liddle, P. Neurobiology of psychosis and schizophrenia 2022: Nottingham meeting. Compr. Psychiatry 2023, 127, 152415. [Google Scholar] [CrossRef] [Scilit]
- Miniawi, S.E.; Orgeta, V.; Stafford, J. Non-affective psychotic disorders and risk of dementia: A systematic review and meta-analysis. Psychol. Med. 2022, 52, 3323–3335. [Google Scholar] [CrossRef] [Scilit]
- McCutcheon, R.A.; Keefe, R.S.E.; McGuire, P.K. Cognitive impairment in schizophrenia: Aetiology, pathophysiology, and treatment. Mol. Psychiatry 2023, 28, 1902–1918. [Google Scholar] [CrossRef] [Scilit]
- Laganà, V.; Bruno, F.; Altomari, N.; Bruni, G.; Smirne, N.; Curcio, S.; Mirabelli, M.; Colao, R.; Puccio, G.; Frangipane, F.; et al. Neuropsychiatric or Behavioral and Psychological Symptoms of Dementia (BPSD): Focus on prevalence and natural history in Alzheimer’s disease and frontotemporal dementia. Front. Neurol. 2022, 13, 832199. [Google Scholar] [CrossRef] [Scilit]
- Müller-Spahn, F. Behavioral disturbances in dementia. Dialogues Clin. Neurosci. 2003, 5, 49–59. [Google Scholar] [CrossRef] [Scilit]
- Pinyopornpanish, K.; Soontornpun, A.; Wongpakaran, T.; Wongpakaran, N.; Tanprawate, S.; Pinyopornpanish, K.; Nadsasarn, A.; Pinyopornpanish, M. Impact of behavioral and psychological symptoms of Alzheimer’s disease on caregiver outcomes. Sci. Rep. 2022, 12, 14138. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Cressot, C.; Vrillon, A.; Lilamand, M.; Francisque, H.; Méauzoone, A.; Hourregue, C.; Dumurgier, J.; Marlinge, E.; Paquet, C.; Cognat, E. Psychosis in neurodegenerative dementias: A systematic comparative review. J. Alzheimers Dis. 2024, 99, 85–99. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Morrow, C.B.; Pontone, G.M. Exploring psychosis in neurodegenerative dementia: Connecting symptoms to neurobiology. J. Alzheimers Dis. 2024, 99, 101–103. [Google Scholar] [CrossRef] [Scilit]
- Mühlbauer, V.; Möhler, R.; Dichter, M.N.; Zuidema, S.U.; Köpke, S.; Luijendijk, H.J. Antipsychotics for agitation and psychosis in people with Alzheimer’s disease and vascular dementia. Cochrane Database Syst. Rev. 2021, 12, CD013304. [Google Scholar] [CrossRef] [Scilit]
- Saint-Georges, Z.; MacDonald, J.; Al-Khalili, R.; Hamati, R.; Solmi, M.; Keshavan, M.S.; Tuominen, L.; Guimond, S. Cholinergic system in schizophrenia: A systematic review and meta-analysis. Mol. Psychiatry 2025, 30, 3301–3315. [Google Scholar] [CrossRef] [Scilit]
- Cuello, A.C. The involvement of the cholinergic system in Alzheimer disease. In Handbook of Clinical Neurology; Elsevier: Amsterdam, The Netherlands, 2025; Volume 211, pp. 63–79. [Google Scholar] [CrossRef] [Scilit]
- Wang, L.; Shang, S.; Kang, X.; Teng, S.; Zhu, F.; Liu, B.; Wu, Q.; Li, M.; Liu, W.; Xu, H.; et al. Modulation of dopamine release in the striatum by physiologically relevant levels of nicotine. Nat. Commun. 2014, 5, 3925. [Google Scholar] [CrossRef] [Scilit]
- Aosaki, T.; Miura, M.; Suzuki, T.; Nishimura, K.; Masuda, M. Acetylcholine-dopamine balance hypothesis in the striatum: An update. Geriatr. Gerontol. Int. 2010, 10, S148–S157. [Google Scholar] [CrossRef] [Scilit]
- Beurel, E.; Grieco, S.F.; Jope, R.S. Glycogen synthase kinase-3 (GSK-3): Regulation, actions, and diseases. Pharmacol. Ther. 2015, 148, 114–131. [Google Scholar] [CrossRef] [Scilit]
- Hampel, H.; Lista, S.; Vanmechelen, E.; Zetterberg, H.; Giorgi, F.S.; Galgani, A.; Blennow, K.; Caraci, F.; Das, B.; Yan, R.; et al. β-Secretase-1 biological markers for Alzheimer’s disease: State-of-the-art of validation and qualification. Alzheimers Res. Ther. 2020, 12, 130. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Jiang, X.; Li, J.; Yao, X.; Ding, H.; Gu, A.; Zhou, Z. Neuroprotective effects of dipeptidyl peptidase-4 inhibitor on Alzheimer’s disease: A narrative review. Front. Pharmacol. 2024, 15, 1361651. [Google Scholar] [CrossRef] [Scilit]
- Ng, F.; Berk, M.; Dean, O.; Bush, A.I. Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. 2008, 11, 851–876. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Trofin, D.M.; Sardaru, D.P.; Trofin, D.; Onu, I.; Tutu, A.; Onu, A.; Oniță, C.; Galaction, A.I.; Matei, D.V. Oxidative stress in brain function. Antioxidants 2025, 14, 297. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Üremiş, N.; Üremiş, M.M. Oxidative/nitrosative stress, apoptosis, and redox signaling: Key players in neurodegenerative diseases. J. Biochem. Mol. Toxicol. 2025, 39, e70133. [Google Scholar] [CrossRef] [Scilit]
- Khokhar, J.Y.; Henricks, A.M.; Sullivan, E.D.K.; Green, A.I. Unique effects of clozapine: A pharmacological perspective. In Advances in Pharmacology; Elsevier: Amsterdam, The Netherlands, 2018; Volume 82, pp. 137–162. [Google Scholar] [CrossRef] [Scilit]
- Chen, A.T.; Nasrallah, H.A. Neuroprotective effects of the second-generation antipsychotics. Schizophr. Res. 2019, 208, 1–7. [Google Scholar] [CrossRef] [Scilit]
- Hu, X.; Zhou, H.; Zhang, D.; Yang, S.; Qian, L.; Wu, H.M.; Chen, P.S.; Wilson, B.; Gao, H.M.; Lu, R.B.; et al. Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation. J. Neuroimmune Pharmacol. 2012, 7, 187–201. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Amerio, A.; Magnani, L.; Arduino, G.; Fesce, F.; de Filippis, R.; Parise, A.; Costanza, A.; Nguyen, K.D.; Saverino, D.; De Berardis, D.; et al. Immunomodulatory effects of clozapine: More than just a side effect in schizophrenia. Curr. Neuropharmacol. 2024, 22, 1233–1247. [Google Scholar] [CrossRef] [Scilit]
- Zhang, L.; Zhou, Y.; Xie, Y.; Ying, Y.; Li, Y.; Ye, S.; Wang, Z. Adjunctive clozapine with bright light mitigates cognitive deficits by synaptic plasticity and neurogenesis in sub-chronic MK-801-treated mice. Pharmacol. Biochem. Behav. 2024, 243, 173821. [Google Scholar] [CrossRef] [Scilit]
- Chung, Y.C.; Li, Z.; Dai, J.; Meltzer, H.Y.; Ichikawa, J. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: Role of 5-HT1A receptor agonism. Brain Res. 2004, 1023, 54–63. [Google Scholar] [CrossRef] [Scilit]
- Gassó, P.; Martínez-Pinteño, A.; Rodríguez, N.; Madero, S.; Gómez, M.; Segura, A.G.; García-Rizo, C.; Morén, C.; Mas, S.; Parellada, E. Neurotoxic/neuroprotective effects of clozapine and the positive allosteric modulator of mGluR2 JNJ-46356479 in human neuroblastoma cell cultures. Int. J. Mol. Sci. 2023, 24, 2054. [Google Scholar] [CrossRef] [Scilit]
- Arfeen, M.; Dhaked, D.K.; Mani, V. Multipotent effect of clozapine on lipopolysaccharide-induced acetylcholinesterase, cyclooxygenase-2, 5-lipoxygenase, and caspase-3: In vivo and molecular modeling studies. Molecules 2025, 30, 266. [Google Scholar] [CrossRef] [Scilit]
- Percie du Sert, N.; Hurst, V.; Ahluwalia, A.; Alam, S.; Avey, M.T.; Baker, M.; Browne, W.J.; Clark, A.; Cuthill, I.C.; Dirnagl, U.; et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. Br. J. Pharmacol. 2020, 177, 3617–3624. [Google Scholar] [CrossRef] [Scilit]
- Mani, V.; Arfeen, M. Betahistine’s neuroprotective actions against lipopolysaccharide-induced neurotoxicity: Insights from experimental and computational studies. Brain Sci. 2024, 14, 876. [Google Scholar] [CrossRef] [Scilit]
- Alshammari, A.A.A.; Arfeen, M.; Alkhamiss, A.S.; Alwesmi, M.B.; Mani, V. Montelukast’s potential as a neuroprotective agent against acrylamide-induced neurotoxicity: In vivo and computational modelling. Food Chem. Toxicol. 2025, 201, 115448. [Google Scholar] [CrossRef] [Scilit]
- Golkar, A.; Dalfardi, M.; Hedayati-Moghadam, M.; Askarpour, H.; Hosseini, M.; Baghcheghi, Y. Understanding the neurobiological mechanisms of LPS-induced memory impairment. Acta Neurobiol. Exp. 2025, 84, 371–394. [Google Scholar] [CrossRef] [Scilit]
- Choi, Y.; Jeong, H.J.; Liu, Q.F.; Oh, S.T.; Koo, B.S.; Kim, Y.; Chung, I.W.; Kim, Y.S.; Jeon, S. Clozapine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer’s disease. Mol. Neurobiol. 2017, 54, 450–460. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ilg, A.K.; Enkel, T.; Bartsch, D.; Bähner, F. Behavioral effects of acute systemic low-dose clozapine in wild-type rats: Implications for the use of DREADDs in behavioral neuroscience. Front. Behav. Neurosci. 2018, 12, 173. [Google Scholar] [CrossRef] [Scilit]
- Alzahrani, N.A.; Bahaidrah, K.A.; Mansouri, R.A.; Alsufiani, H.M.; Alghamdi, B.S. Investigation of the optimal dose for experimental lipopolysaccharide-induced recognition memory impairment: Behavioral and histological studies. J. Integr. Neurosci. 2022, 21, 49. [Google Scholar] [CrossRef] [Scilit]
- Antonio, C.B.; Betti, A.H.; Herzfeldt, V.; Barreiro, E.J.; Fraga, C.A.; Rates, S.M. LASSBio-579, a prototype antipsychotic drug, and clozapine are effective in the novel object recognition task, a recognition memory model. Behav. Pharmacol. 2016, 27, 339–349. [Google Scholar] [CrossRef] [Scilit]
- Mutlu, O.; Ulak, G.; Celikyurt, I.K.; Akar, F.Y.; Erden, F.; Tanyeri, P. Effects of olanzapine, sertindole and clozapine on MK-801-induced visual memory deficits in mice. Pharmacol. Biochem. Behav. 2011, 99, 557–565. [Google Scholar] [CrossRef] [Scilit]
- Hoffman, K.L.; Basurto, E. Clozapine and glycinamide prevent MK-801-induced deficits in the novel object recognition test in the domestic rabbit (Oryctolagus cuniculus). Behav. Brain Res. 2014, 271, 203–211. [Google Scholar] [CrossRef] [Scilit]
- Bahaidrah, K.A.; Alzahrani, N.A.; Aldhahri, R.S.; Mansouri, R.A.; Alghamdi, B.S. Effects of different lipopolysaccharide doses on short- and long-term spatial memory and hippocampus morphology in an experimental Alzheimer’s disease model. Clin. Transl. Neurosci. 2022, 6, 20. [Google Scholar] [CrossRef] [Scilit]
- Addy, N.A.; Pocivavsek, A.; Levin, E.D. Reversal of clozapine effects on working memory in rats with fimbria-fornix lesions. Neuropsychopharmacology 2005, 30, 1121–1127. [Google Scholar] [CrossRef] [Scilit]
- Chen, Z.R.; Huang, J.B.; Yang, S.L.; Hong, F.F. Role of cholinergic signaling in Alzheimer’s disease. Molecules 2022, 27, 1816. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Carnac, T. Schizophrenia hypothesis: Autonomic nervous system dysregulation of fetal and adult immune tolerance. Front. Syst. Neurosci. 2022, 16, 844383. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Avram, M.; Grothe, M.J.; Meinhold, L.; Leucht, C.; Leucht, S.; Borgwardt, S.; Brandl, F.; Sorg, C. Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia. Neuropsychopharmacology 2021, 46, 2320–2329. [Google Scholar] [CrossRef] [Scilit]
- Zhao, J.; Wei, M.; Guo, M.; Wang, M.; Niu, H.; Xu, T.; Zhou, Y. GSK3: A potential target and pending issues for treatment of Alzheimer’s disease. CNS Neurosci. Ther. 2024, 30, e14818. [Google Scholar] [CrossRef] [Scilit]
- Hernandez, F.; Lucas, J.J.; Avila, J. GSK3 and tau: Two convergence points in Alzheimer’s disease. J. Alzheimers Dis. 2013, 33, S141–S144. [Google Scholar] [CrossRef] [Scilit]
- Ebeid, M.A.; Habib, M.Z.; Mohamed, A.M.; Faramawy, Y.E.; Saad, S.S.T.; El-Kharashi, O.A.; El Magdoub, H.M.; Abd-Alkhalek, H.A.; Aboul-Fotouh, S.; Abdel-Tawab, A.M. Cognitive effects of the GSK-3 inhibitor lithium in an LPS/chronic mild stress rat model of depression: Hippocampal and cortical neuroinflammation and tauopathy. Neurotoxicology 2021, 83, 77–88. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zhao, J.; Fu, Y.; Yasvoina, M.; Shao, P.; Hitt, B.; O’Connor, T.; Logan, S.; Maus, E.; Citron, M.; Berry, R.; et al. β-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: Implications for Alzheimer’s disease pathogenesis. J. Neurosci. 2007, 27, 3639–3649. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Prabha, S.; Sajad, M.; Hasan, G.M.; Islam, A.; Hassan, M.I.; Thakur, S.C. Recent advancement in understanding of Alzheimer’s disease: Risk factors, subtypes, and drug targets and potential therapeutics. Ageing Res. Rev. 2024, 101, 102476. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ghosh, A.K. BACE1 inhibitor drugs for the treatment of Alzheimer’s disease: Lessons learned, challenges to overcome, and future prospects. Glob. Health Med. 2024, 6, 164–168. [Google Scholar] [CrossRef] [Scilit]
- Sulangi, A.J.; Lyons, S.E.; Abdou, A.A.; Patel, H.; Nagliya, D.; Joseph, E.; Joseph, C.; Kumar, D.; Patel, S.; Jinwala, I.; et al. Exploring the therapeutic potential of DPP4 inhibitors in Alzheimer’s disease: Molecular insight and clinical outcome. Cureus 2024, 16, e72648. [Google Scholar] [CrossRef] [Scilit]
- Kim, S.; Jung, U.J.; Kim, S.R. Role of oxidative stress in blood–brain barrier disruption and neurodegenerative diseases. Antioxidants 2024, 13, 1462. [Google Scholar] [CrossRef] [Scilit]
- Dos Santos, M.P.; Leocadio, V.E.; de Sá Hayashide, L.; Marques, M.; Carvalho, C.F.; Galina, A.; Diniz, L.P. Lipopolysaccharide induces mitochondrial fragmentation and energetic shift in reactive microglia: Evidence for a cell-autonomous program of metabolic plasticity. Toxins 2025, 17, 293. [Google Scholar] [CrossRef] [Scilit]
- Nandi, A.; Yan, L.J.; Jana, C.K.; Das, N. Role of catalase in oxidative stress- and age-associated degenerative diseases. Oxid. Med. Cell. Longev. 2019, 2019, 9613090. [Google Scholar] [CrossRef] [Scilit]
- Aoyama, K. Glutathione in the brain. Int. J. Mol. Sci. 2021, 22, 5010. [Google Scholar] [CrossRef] [Scilit]
- Essadek, S.; Bouchab, H.; El Kebbaj, R.; Gondcaille, C.; El Kamouni, S.; Savary, S.; Vamecq, J.; Essamadi, A.; Cherkaoui-Malki, M.; Nasser, B.; et al. Effects of a short-term lipopolysaccharide challenge on mouse brain and liver peroxisomal antioxidant and β-oxidative functions: Protective action of argan oil. Pharmaceuticals 2022, 15, 465. [Google Scholar] [CrossRef] [Scilit]
- Huang, S.; Lu, Y.; Fang, W.; Huang, Y.; Li, Q.; Xu, Z. Neurodegenerative diseases and neuroinflammation-induced apoptosis. Open Life Sci. 2025, 20, 20221051. [Google Scholar] [CrossRef] [Scilit]
- Chipuk, J.E.; Green, D.R. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol. 2008, 18, 157–164. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Nguyen, T.T.M.; Gillet, G.; Popgeorgiev, N. Caspases in the developing central nervous system: Apoptosis and beyond. Front. Cell Dev. Biol. 2021, 9, 702404. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Vogler, M.; Braun, Y.; Smith, V.M.; Westhoff, M.A.; Pereira, R.S.; Pieper, N.M.; Anders, M.; Callens, M.; Vervliet, T.; Abbas, M.; et al. The BCL2 family: From apoptosis mechanisms to new advances in targeted therapy. Signal Transduct. Target. Ther. 2025, 10, 91. [Google Scholar] [CrossRef] [Scilit]
- Steinberg, M.; Lyketsos, C.G. Atypical antipsychotic use in patients with dementia: Managing safety concerns. Am. J. Psychiatry 2012, 169, 900–906. [Google Scholar] [CrossRef] [Scilit]
- Hashemi, N.; Yang, D.; Shergold, D.; Tennen, G.; Fan-Lun, C. Clozapine for management of neuropsychiatric symptoms in dementia with Lewy Bodies: Case report and literature review. Can. J. Hosp. Pharm. 2023, 764, 340–345. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.







